Objective To analyze the intervention effect of the dose-dense schemes of temozolomide on the newly diagnosed glioblastoma compared with the standard schemes. Methods The Pubmed,Cochrane,Em-base,CNKI,CBM,Wanfang,VIP databases were used for the retrievals on the intervention effect.The quality of included papers was assessed to extract network meta-analysis data with using the statistical software Stata 13.0. Results The treatment plans were ranked according to the intervention effect from the best to the worst as follows:the dose-dense,the early,the metronomic,the standard,the RT and post-RT adjuvant temozolomide. The most common adverse effects in hematotoxicity were neutropenia,leucopenia,lymphopenia,thrombocytopenia and ane-mia. Between the different temozolomide therapeutic regimens,there was no significant difference. Conclusion The intervention effect of the dose-dense schemes with temozolomide is better than the standard therapy. It also revealed that,the hematoxicity in the different temozolomide schemes is not significantly different.%目的 探讨高剂量替莫唑胺治疗方案与标准替莫唑胺治疗方案在新诊断胶质母细胞瘤患者中的疗效.方法 分别检索Pubmed,Cochrane,Embase、知网,万方,维普,CBM各数据库;对纳入文章进行质量评估,数据提取后采用Stata13.0进行网状Meta分析.结果 分析揭示:替莫唑胺治疗方案的有效性排序从高到低依次是高剂量治疗方案、早期治疗方案、规律治疗方案、标准治疗方案、放疗和放疗后辅助替莫唑胺治疗方案.副作用方面,分析揭示:最常见的血液学不良反应包括白细胞、嗜中性粒细胞、淋巴细胞和血小板减少症,贫血;各自发生率在不同治疗组差异无统计学意义.结论 在新诊断的胶质母细胞瘤患者中,高剂量替莫唑胺治疗方案的干预效果优于标准替莫唑胺治疗方案,且不同类型的血液毒性反应发生率在不同干预组差异无统计学意义.
展开▼
